CYCNCyclerion Therapeutics, Inc.
- Earnings Call Transcripts
ANNUAL MEETING OF SHAREHOLDERS - CYCLERION THERAPEUTICS INC
Thank you for watching. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. © transcript Emily Beynon T ...
- Earnings Call Transcripts
ANNUAL MEETING OF SHAREHOLDERS - CYCLERION THERAPEUTICS INC
Thank you for watching. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. © transcript Emily Beynon T ...
- PR Newswire
Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws... ...
- PR Newswire
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws... ...
- PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--CYCN, CECO, THR, and CWAN
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for... ...
- PR Newswire
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for... ...
- PR Newswire
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced... ...
- BusinessWire
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases Korsana's lead program KRSA-028 is a next-generation shuttled ...
- GlobeNewswire
Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board
–Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, ...
- GlobeNewswire
Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and ...
- GlobeNewswire
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression
– Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer – – Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept ("POC") ...
- SEC
SCHEDULE 13G Form - Statement of Beneficial Ownership by Certain Investors - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
Statement of Beneficial Ownership by Certain Investors ...
- SEC
8-K Form - Current report, items 1.01, 7.01, and 9.01 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Current report, items 1.01, 7.01, and 9.01 ...
- GlobeNewswire
Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company
– Cyclerion Relaunches, Advancing a Phase 2–Ready Program for Millions Living with Treatment-Resistant Depression Through MIT License Agreement – – Webcast to be held September 24, 2025 at 10:30 a.m. ET – CAMBRIDGE, ...
- SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Quarterly report [Sections 13 or 15(d)] ...
- SEC
8-K Form - Current report, items 5.07 and 9.01 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Current report, items 5.07 and 9.01 ...
- SEC
EFFECT Form - Notice of Effectiveness - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Notice of Effectiveness ...
- SEC
SCHEDULE 13G/A Form - [Amend] Statement of Beneficial Ownership by Certain Investors - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
[Amend] Statement of Beneficial Ownership by Certain Investors ...
- SEC
8-K Form - Current report, items 1.01 and 9.01 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Current report, items 1.01 and 9.01 ...
- SEC
424B5 Form - Prospectus [Rule 424(b)(5)] - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Prospectus [Rule 424(b)(5)] ...
- SEC
S-3 Form - Registration statement under Securities Act of 1933 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Registration statement under Securities Act of 1933 ...
- SEC
DEFA14A Form - Additional definitive proxy soliciting materials and Rule 14(a)(12) material - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Additional definitive proxy soliciting materials and Rule 14(a)(12) material ...
- SEC
DEF 14A Form - Other definitive proxy statements - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Other definitive proxy statements ...
- SEC
SCHEDULE 13D/A Form - [Amend] General Statement of Acquisition of Beneficial Ownership - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
[Amend] General Statement of Acquisition of Beneficial Ownership ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
Statement of changes in beneficial ownership of securities ...